BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...and CFO. He held the same position at Novelion Therapeutics Inc. (NASDAQ:NVLN). Gene therapy company Horama S.A....
...Staff Merck & Co. Inc. Ping An Healthcare and Technology Co. Ltd. Mirati Therapeutics Inc. Evox Therapeutics Ardelyx Inc. Akcea Therapeutics Inc. Horama S.A. Cellectis...
BioCentury | May 6, 2020
Management Tracks

Abrams resigns as Editas CMO; plus Immunocore, Spruce, Frazier, Horama and more

...as CMO, and McMurray was CSO and a co-founder of Outpost. Ophthalmology gene therapy company Horama S.A....
...firm Ceutec LLC, which he founded. Robin Sawka, BioCentury Staff Editas Medicine Inc. Immunocore Ltd. Spruce Biosciences Inc. Frazier Healthcare Partners Horama S.A. Nordic...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

...company Pharming Group N.V. (Euronext:PHARM) said CFO Robin Wright will step down, effective May 20. Horama...
...Inc. Akcea Therapeutics Inc. Refuge Biotechnologies Inc. GammaDelta Therapeutics Ltd. Thermo Fisher Scientific Inc. Fujifilm Holdings Corp. NGM Biopharmaceuticals Inc. Pharming Group N.V. Horama S.A. Vectura...
BioCentury | Sep 21, 2018
Financial News

Gene therapy company Horama closes series B at €22.5M

...€19 million ($22.2 million) in the round from Kurma Partners, Fund+, Pontifax and Idinvest Partners. Horama’s...
...serotype 5 recombinant adeno-associated virus (rAAV) delivering the phosphodiesterase-6B (PDE-6B) gene. Horama S.A., Paris, France Jaime De Leon HORA-PDE6B Horama S.A. Phosphodiesterase-6B...
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

...Chintu Patel, who was co-CEO, co-chairman and co-founder of Amneal Pharmaceuticals Inc. (NYSE:AMRX). Ophthalmology company Horama S.A....
BioCentury | Nov 10, 2017
Financial News

Horoma raises €19M for gene therapies

...series B round led by Kurma Partners, Fund+, Pontifax and Idinvest Partners. According to Kurma, Horama...
...advanced product is HORA-RPE65 to treat Leber’s congenital amaurosis (LCA) type 2. Horama S.A., Paris, France Shannon Lehnbeuter Horama S.A....
BioCentury | Nov 9, 2017
Financial News

Horama raises €19M for gene therapies

...series B round led by Kurma Partners, Fund+, Pontifax and Idinvest Partners. According to Kurma, Horama...
...of HORA-PDE6B “soon” to treat retinitis pigmentosa caused by mutations in the phosphodiesterase-6B (PDE6B) gene. Horama’s...
BioCentury | Nov 5, 2016
Finance

Vive la biotech

...company Horama S.A.S. has HORA-RPE65 in Phase I/II testing to treat Leber’s congenital amaurosis (LCA). Horama...
...Pharma S.A., Toulouse, France Genfit S.A. (Euronext:GNFT), Loos, France GenSight Biologics S.A. (Euronext:SIGHT), Paris, France Horama...
...Hansen, Associate Editor Cellectis S.A. DBV Technologies S.A. Eligo Bioscience S.A.S. Enterome Bioscience S.A. Enyo Pharma GamaMabs Pharma S.A. Genfit S.A. GenSight Biologics S.A. Horama...
BioCentury | Jul 11, 2016
Financial News

Horama completes venture financing

Horama S.A.S. , Paris, France Business: Gene/Cell therapy, Ophthalmic Date completed: 2016-07-08 Type: Venture financing Raised: EUR4 million ($4.4 million) Investors: Omnes Capital; Sham; GO Capital Fund WIR Staff Ophthalmic...
BioCentury | Jul 27, 2015
Strategy

Rules of competition

...Phase I/II trials, but neither is in active development: rAAV2-CB-rhRPE65 from AGTC and HORA-RPE65 from Horama...
...Horama, however, decided to deprioritize its RPE65 product because Spark was so much further ahead. Horama...
...Mass. Celladon Corp. (NASDAQ:CLDN), San Diego, Calif. Dimension Therapeutics Inc., Cambridge, Mass. Genethon, Evry, France Horama...
Items per page:
1 - 10 of 12
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...and CFO. He held the same position at Novelion Therapeutics Inc. (NASDAQ:NVLN). Gene therapy company Horama S.A....
...Staff Merck & Co. Inc. Ping An Healthcare and Technology Co. Ltd. Mirati Therapeutics Inc. Evox Therapeutics Ardelyx Inc. Akcea Therapeutics Inc. Horama S.A. Cellectis...
BioCentury | May 6, 2020
Management Tracks

Abrams resigns as Editas CMO; plus Immunocore, Spruce, Frazier, Horama and more

...as CMO, and McMurray was CSO and a co-founder of Outpost. Ophthalmology gene therapy company Horama S.A....
...firm Ceutec LLC, which he founded. Robin Sawka, BioCentury Staff Editas Medicine Inc. Immunocore Ltd. Spruce Biosciences Inc. Frazier Healthcare Partners Horama S.A. Nordic...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

...company Pharming Group N.V. (Euronext:PHARM) said CFO Robin Wright will step down, effective May 20. Horama...
...Inc. Akcea Therapeutics Inc. Refuge Biotechnologies Inc. GammaDelta Therapeutics Ltd. Thermo Fisher Scientific Inc. Fujifilm Holdings Corp. NGM Biopharmaceuticals Inc. Pharming Group N.V. Horama S.A. Vectura...
BioCentury | Sep 21, 2018
Financial News

Gene therapy company Horama closes series B at €22.5M

...€19 million ($22.2 million) in the round from Kurma Partners, Fund+, Pontifax and Idinvest Partners. Horama’s...
...serotype 5 recombinant adeno-associated virus (rAAV) delivering the phosphodiesterase-6B (PDE-6B) gene. Horama S.A., Paris, France Jaime De Leon HORA-PDE6B Horama S.A. Phosphodiesterase-6B...
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

...Chintu Patel, who was co-CEO, co-chairman and co-founder of Amneal Pharmaceuticals Inc. (NYSE:AMRX). Ophthalmology company Horama S.A....
BioCentury | Nov 10, 2017
Financial News

Horoma raises €19M for gene therapies

...series B round led by Kurma Partners, Fund+, Pontifax and Idinvest Partners. According to Kurma, Horama...
...advanced product is HORA-RPE65 to treat Leber’s congenital amaurosis (LCA) type 2. Horama S.A., Paris, France Shannon Lehnbeuter Horama S.A....
BioCentury | Nov 9, 2017
Financial News

Horama raises €19M for gene therapies

...series B round led by Kurma Partners, Fund+, Pontifax and Idinvest Partners. According to Kurma, Horama...
...of HORA-PDE6B “soon” to treat retinitis pigmentosa caused by mutations in the phosphodiesterase-6B (PDE6B) gene. Horama’s...
BioCentury | Nov 5, 2016
Finance

Vive la biotech

...company Horama S.A.S. has HORA-RPE65 in Phase I/II testing to treat Leber’s congenital amaurosis (LCA). Horama...
...Pharma S.A., Toulouse, France Genfit S.A. (Euronext:GNFT), Loos, France GenSight Biologics S.A. (Euronext:SIGHT), Paris, France Horama...
...Hansen, Associate Editor Cellectis S.A. DBV Technologies S.A. Eligo Bioscience S.A.S. Enterome Bioscience S.A. Enyo Pharma GamaMabs Pharma S.A. Genfit S.A. GenSight Biologics S.A. Horama...
BioCentury | Jul 11, 2016
Financial News

Horama completes venture financing

Horama S.A.S. , Paris, France Business: Gene/Cell therapy, Ophthalmic Date completed: 2016-07-08 Type: Venture financing Raised: EUR4 million ($4.4 million) Investors: Omnes Capital; Sham; GO Capital Fund WIR Staff Ophthalmic...
BioCentury | Jul 27, 2015
Strategy

Rules of competition

...Phase I/II trials, but neither is in active development: rAAV2-CB-rhRPE65 from AGTC and HORA-RPE65 from Horama...
...Horama, however, decided to deprioritize its RPE65 product because Spark was so much further ahead. Horama...
...Mass. Celladon Corp. (NASDAQ:CLDN), San Diego, Calif. Dimension Therapeutics Inc., Cambridge, Mass. Genethon, Evry, France Horama...
Items per page:
1 - 10 of 12